Search for "dipeptide" in Full Text gives 92 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2026, 22, 705–741, doi:10.3762/bjoc.22.55
Graphical Abstract
Scheme 1: Strategies for the preparation of pyrrolidine derivatives by (3 + 2) cycloaddition of azomethine yl...
Scheme 2: (3 + 2) Cycloaddition of iminoesters to dimethylmaleate.
Scheme 3: Cycloaddition of 1 with various dipolarophiles catalyzed by Ag(I)-L1.
Scheme 4: Cycloaddition of 1 with tert-butyl acrylate catalyzed by Ag(I)-L2.
Scheme 5: Cycloaddition of 1 with dimethyl maleate catalyzed by Cu(I)-L3.
Scheme 6: Cycloaddition of 1 with alkenes catalyzed by Zn(II)-t-Bu-BOX (L4).
Scheme 7: (3 + 2) Cycloaddition of iminoesters to acrylates.
Scheme 8: Catalytic double (3 + 2) cycloaddition to form pyrrolizidine derivatives.
Scheme 9: (3 + 2) Cycloaddition of iminoethers to vinyl phenyl sulfone.
Scheme 10: Regiodivergent and enantioselective synthesis of pyrrolidines 16 and 17.
Scheme 11: Substrate-controlled regioreversible "normal" and "incomplete" 1,3-dipolar cycloaddition.
Scheme 12: Enantioselective synthesis of exo-/endo-pyrrolidines.
Scheme 13: (3 + 2) Cycloaddition of iminoethers 21 to dipolarophiles 22–24.
Scheme 14: Synthesis of bicyclic pyrrolidines 29 from cyclopentene-1,3-diones.
Scheme 15: (3 + 2) Cycloaddition of aldimine esters and allyl alcohols using copper-ruthenium catalysis.
Scheme 16: Synthesis of 3,3-difluoro- and 3,3,4-trifluoropyrrolidine derivatives.
Scheme 17: Use of iminoesters from natural compounds and pharmaceuticals for reactions with 1,1-difluoro- and ...
Scheme 18: Reaction of iminoesters with 1,3-enynes.
Scheme 19: Synthesis of pyrrolidines from iminoesters and vinyl(hetero)arenes.
Scheme 20: Synthesis of exo-pyrrolidines 42 and 43.
Scheme 21: Enantioselective synthesis of heteroarylpyrrolidines 45 and 46.
Scheme 22: Catalytic reaction of (3 + 2) cycloaddition of imines 12 to benzofulvenes 47.
Scheme 23: Fullerene as a dipolarophile in (3 + 2) cycloaddition reactions.
Scheme 24: Asymmetric synthesis of optically active tetrasubstituted pyrrolidines 54.
Scheme 25: (3 + 2) Cycloaddition reaction of imines 55 and α,β-unsaturated aldehydes.
Scheme 26: Probable mechanism of enantioselective (3 + 2) cycloaddition of azomethine ylides to α,β-unsaturate...
Scheme 27: Cycloaddition between iminoesters 12 and sulfinylimines 58.
Scheme 28: (3 + 2) Cycloaddition between triarylideneacetylacetone and azomethine ylides in the presence of ti...
Scheme 29: Stereoselective synthesis of decahydropyrrolo[2,1,5-cd]indolizine 66.
Scheme 30: Synthesis of policyclic derivatives 71 and 72.
Scheme 31: Catalytic аsymmetric (3 + 2) сycloaddition of 2-pyridylimines with N-methylmaleimide.
Scheme 32: Catalytic аsymmetric (3 + 2) сycloaddition of 2-pyridylimines 1 with other dipolarophiles.
Scheme 33: Enantioselective (3 + 2) cycloaddition of silylimine with various dipolarophiles.
Scheme 34: Proposed mechanism of formation of pyrrolidines 78.
Scheme 35: Synthesis of polyheterocyclic pyrrolidines 82–91.
Scheme 36: Synthesis of spirocyclic (95) and fused (96) pyrrolidines.
Scheme 37: (3 + 2) Cycloaddition involving aromatic aldehydes 97, N-propargylmaleimide (98) and α-amino acids ...
Scheme 38: Synthesis of pyrrolizidines 106 and by-product 107.
Scheme 39: Iridium-catalyzed three-component cascade (3 + 2) cycloaddition.
Scheme 40: Intramolecular (3 + 2) cycloaddition of N-alkenylpyrrole-2-carbaldehyde 110 and α-amino acids.
Scheme 41: Three-component (3 + 2) cycloaddition involving fullerene.
Scheme 42: Four-component stereoselective one-pot synthesis of spiro-cycloadducts 119–122.
Scheme 43: Reactions of azomethine ylide 123 with cyclopropenes.
Scheme 44: Three-component reactions involving ninhydrin, cyclopropenes and acyclic α-amino acids.
Scheme 45: Reaction of cyclopropenes 138 with the N-protonated form of Ruhemann purple 137.
Scheme 46: Enantioselective (3 + 2) cycloaddition of azomethine ylides generated in situ from isatins and amin...
Scheme 47: (3 + 2) Cycloaddition of cyclohexenone 143, isatins 140 and aminomalonic diesters 141, catalyzed by...
Scheme 48: Enantioselective (3 + 2) cycloaddition of azomethine ylides generated in situ from isatins and amin...
Scheme 49: Enantioselective (3 + 2) cycloaddition of azomethine ylides generated in situ from isatins and benz...
Scheme 50: (3 + 2) Cycloaddition involving isatins, azetidine-2-carboxylic acid, maleimides or itaconimides.
Scheme 51: (3 + 2) Cycloaddition involving isatins, amino acids and tetraethylvinylidenebis(phosphonate).
Scheme 52: Synthesis of spirooxindoles 156 from triarylideneacetylacetones 155.
Scheme 53: Synthesis of spirooxindole derivatives 157–160.
Scheme 54: Synthesis of hybrid spiro-heterocycles 164–166.
Scheme 55: Formation of azomethine ylide from isatin and sarcosine.
Scheme 56: (3 + 2) Cycloaddition involving isatins, amino acids and trans-3-benzoylacrylic acid.
Scheme 57: Regioselective synthesis of spirooxindoles 170.
Scheme 58: Synthesis of hybrid spiro-heterocycles 86.
Scheme 59: (3 + 2) Cycloaddition involving acenaphthenequinones, amino acids and cyclopropenes.
Scheme 60: Synthesis of hybrid glyco-3-nitrochromane cycloadducts 179.
Scheme 61: Synthesis of spiro[indenoquinoxaline-(thia)pyrrolizidines] 90a.
Scheme 62: Three-component reactions of cyclopropenes, 11H-indeno[1,2-b]quinoxalin-11-onesand α-amino acids, s...
Scheme 63: Synthesis of hybrid glyco-3-nitrochromane cycloadducts 92.
Scheme 64: (3 + 2) Cycloaddition of 11H-benzo[4,5]imidazo[1,2-a]indol-11-one (189) with cyclopropenes and male...
Scheme 65: Diastereoselective synthesis of spiro derivatives of barbituric acid from alloxan 193, α-amino acid...
Scheme 66: Probable mechanism of formation of azomethine ylide from alloxan and ʟ-proline.
Scheme 67: Three-component reactions involving tryptanthrin 196, α-amino acids and cyclopropenes.
Beilstein J. Org. Chem. 2026, 22, 352–369, doi:10.3762/bjoc.22.23
Graphical Abstract
Scheme 1: a) Resonance structure of amide. b) Concept of twisted amides. c) Transition-metal-catalyzed activa...
Scheme 2: Esterification of amides catalyzed by CeO2.
Scheme 3: Hydrolysis of amides catalyzed by Nb2O5.
Scheme 4: Manganese-catalyzed esterification of tertiary amides.
Scheme 5: Tungsten-catalyzed transamidation of hindered tertiary amides.
Scheme 6: Palladium-catalyzed transamidation of amides.
Scheme 7: Synthesis of benzyl esters via electrophilic activation of amides using DPT-BM.
Scheme 8: Esterification of amides promoted by SO2F2.
Scheme 9: α-Fluorinative cleavage of pyrrolidine-based tertiary amides via double electrophilic activation wi...
Scheme 10: Esterification of primary amides using TCCA via the generation of RCONCl2.
Scheme 11: Esterification of amides via electrophilic activation with Me2SO4.
Scheme 12: HBF4-mediated esterification of amides.
Scheme 13: Synthesis of 2,2,2-trifluoroethyl esters via electrophilic esterification of amide promoted by 67.
Scheme 14: Electrochemical activation of C–N bonds for esterification.
Scheme 15: Catalyst- and reagent-free transamidation of amide using aniline hydrochloride salt.
Scheme 16: CO2-catalyzed transamidation of amides.
Scheme 17: Transamidation of formamides using cyclic dihydrogen tetrametaphosphate.
Scheme 18: BF3·OEt2-mediated transamidation of primary amides.
Scheme 19: Acyl iodide intermediate 121 generation from amides for the transamidation using HOTf and KI.
Scheme 20: Esterification of N,N-dimethyl amides via electrophilic generation of acyl iodide intermediates.
Scheme 21: Transamidation of DMAc promoted by KOt-Bu.
Scheme 22: a) LiHMDS-mediated transamidation of tertiary amides. b) Computed reactivities of selected amides. ...
Scheme 23: Zn-catalyzed chemoselective cleavage of amides directed by tert-butyl nicotinate.
Scheme 24: Chemoselective cleavage of N-PMB anilide for transamidation via acyl fluoride 194 generation. a) Cu...
Beilstein J. Org. Chem. 2026, 22, 1–63, doi:10.3762/bjoc.22.1
Graphical Abstract
Figure 1: Representative alkenyl chloride motifs in natural products. References: Pinnaic acid [8], haterumalide ...
Figure 2: Representative alkenyl chloride motifs in pharmaceuticals and pesticides. References: clomifene [25], e...
Figure 3: Graphical overview of previously published reviews addressing the synthesis of alkenyl chlorides.
Figure 4: Classification of synthetic approaches to alkenyl chlorides.
Scheme 1: Early works by Friedel, Henry, and Favorsky.
Scheme 2: Product distribution obtained by H NMR integration of crude compound as observed by Kagan and co-wo...
Scheme 3: Side reactions observed for the reaction of 14 with PCl5.
Scheme 4: Only compounds 15 and 18 were observed in the presence of Hünig’s base.
Scheme 5: Efficient synthesis of dichloride 15 at low temperatures.
Scheme 6: Various syntheses of alkenyl chlorides on larger scale.
Scheme 7: Scope of the reaction of ketones with PCl5 in boiling cyclohexane.
Scheme 8: Side reactions occur when using excess amounts of PCl5.
Scheme 9: Formation of versatile β-chlorovinyl ketones.
Scheme 10: Mixture of PCl5 and PCl3 used for the synthesis of 49.
Scheme 11: Catechol–PCl3 reagents for the synthesis of alkenyl chlorides.
Scheme 12: (PhO)3P–halogen-based reagents for the synthesis of alkenyl halides.
Scheme 13: Preparation of alkenyl chlorides from alkenyl phosphates.
Scheme 14: Preparation of alkenyl chlorides by treatment of ketones with the Vilsmeier reagent.
Scheme 15: Preparation of electron-rich alkenyl chlorides by treatment of ketones with the Vilsmeier reagent.
Scheme 16: Cu-promoted synthesis of alkenyl chlorides from ketones and POCl3.
Figure 5: GC yield of 9 depending on time and reaction temperature.
Figure 6: Broken reaction flask after attempts to clean the polymerized residue.
Figure 7: GC yield of 9 depending on the amount of CuCl and time.
Scheme 17: Treatment of 4-chromanones with PCl3.
Scheme 18: Synthesis of alkenyl chlorides from the reaction of ketones with acyl chlorides.
Scheme 19: ZnCl2-promoted alkenyl chloride synthesis.
Scheme 20: Regeneration of acid chlorides by triphosgene.
Scheme 21: Alkenyl chlorides from ketones and triphosgene.
Scheme 22: Various substitution reactions.
Scheme 23: Vinylic Finkelstein reactions reported by Evano and co-workers.
Scheme 24: Challenge of selective monohydrochlorination of alkynes.
Scheme 25: Sterically encumbered internal alkynes furnish the hydrochlorination products in high yield.
Scheme 26: Recent work by Kropp with HCl absorbed on alumina.
Scheme 27: High selectivities for monhydrochlorination with nitromethane/acetic acid as solvent.
Figure 8: Functionalized alkynes which typically afford the monhydrochlorinated products.
Scheme 28: Related chorosulfonylation and chloroamination reactions.
Scheme 29: Reaction of organometallic reagents with chlorine electrophiles.
Scheme 30: Elimination reactions of dichlorides to furnish alkenyl chlorides.
Scheme 31: Elimination reactions of allyl chloride 182 to furnish alkenyl chloride 183.
Scheme 32: Detailed studies by Schlosser on the elimination of dichloro compounds.
Scheme 33: Stereoselective variation caused by change of solvent.
Scheme 34: Elimination of gem-dichloride 189 to afford alkene 190.
Scheme 35: Oxidation of enones to dichlorides and in situ elimination thereof.
Scheme 36: Oxidation of allylic alcohols to dichlorides and in situ elimination thereof.
Scheme 37: Chlorination of styrenes with SOCl2 and elimination thereof.
Scheme 38: Chlorination of styrenes with SOCl2 and elimination thereof.
Scheme 39: Fluorine–chlorine exchange followed by elimination.
Scheme 40: Intercepting cations with alkynes and trapping of the alkenyl cation intermediate with chloride.
Scheme 41: Investigations by Mayr and co-workers.
Scheme 42: In situ activation of benzyl alcohol 230 with BCl3.
Scheme 43: In situ activation of benzylic alcohols with TiCl4.
Scheme 44: In situ activation of benzylic alcohols with FeCl3.
Scheme 45: In situ activation of benzylic alcohols with FeCl3.
Scheme 46: In situ activation of aliphatic chlorides and alcohols with ZnCl2, InCl3, and FeCl3.
Scheme 47: In situ generation of benzylic cations and trapping thereof with alkynes.
Scheme 48: Intramolecular trapping reactions affording alkenyl halides.
Scheme 49: Intramolecular trapping reactions affording alkenyl chlorides.
Scheme 50: Intramolecular trapping reactions of oxonium and iminium ions affording alkenyl chlorides.
Scheme 51: Palladium and nickel-catalyzed coupling reactions to afford alkenyl chlorides.
Scheme 52: Rhodium-catalyzed couplings of 1,2-trans-dichloroethene with arylboronic esters.
Scheme 53: First report on monoselective coupling reactions for 1,1-dichloroalkenes.
Scheme 54: Negishi’s and Barluenga’s contributions.
Scheme 55: First mechanistic investigation by Johnson and co-workers.
Scheme 56: First successful cross-metathesis with choroalkene 260.
Scheme 57: Subsequent studies by Johnson.
Scheme 58: Hoveyda and Schrock’s work on stereoretentive cross-metathesis with molybdenum-based catalysts.
Scheme 59: Related work with (Z)-dichloroethene.
Scheme 60: Further ligand refinement and traceless protection of functional groups with HBpin.
Scheme 61: Alkenyl chloride synthesis by Wittig reaction.
Scheme 62: Alkenyl chloride synthesis by Julia olefination.
Scheme 63: Alkenyl chloride synthesis by reaction of ketones with Mg/TiCl4 mixture.
Scheme 64: Frequently used allylic substitution reactions which lead to alkenyl chlorides.
Scheme 65: Enantioselective allylic substitutions.
Scheme 66: Synthesis of alkenyl chlorides bearing an electron-withdrawing group.
Scheme 67: Synthesis of α-nitroalkenyl chlorides from aldehydes.
Scheme 68: Synthesis of alkenyl chlorides via elimination of an in situ generated geminal dihalide.
Scheme 69: Carbenoid approach reported by Pace.
Scheme 70: Carbenoid approach reported by Pace.
Scheme 71: Ring opening of cyclopropenes in the presence of MgCl2.
Scheme 72: Electrophilic chlorination of alkenyl MIDA boronates to Z- or E-alkenyl chlorides.
Scheme 73: Hydroalumination and hydroboration of alkynyl chlorides.
Scheme 74: Carbolithiation of chloroalkynes.
Scheme 75: Chlorination of enamine 420.
Scheme 76: Alkyne synthesis by elimination of alkenyl chlorides.
Scheme 77: Reductive lithiation of akenyl chlorides.
Scheme 78: Reactions of alkenyl chlorides with organolithium reagents.
Scheme 79: Reactions of alkenyl chlorides with organolithium reagents.
Scheme 80: Addition–elimination reaction of alkenyl chloride 9 with organolithium reagents.
Scheme 81: C–H insertions of lithiumcarbenoids.
Scheme 82: Pd-catalyzed coupling reactions with alkenyl chlorides as coupling partner.
Scheme 83: Ni-catalyzed coupling of alkenylcopper reagent with alkenyl chloride 183.
Scheme 84: Ni-catalyzed coupling of heterocycle 472 with alkenyl chloride 473.
Scheme 85: Synthesis of α-chloroketones by oxidation of alkenyl chlorides.
Scheme 86: Tetrahalogenoferrate(III)-promoted oxidation of alkenyl chlorides.
Scheme 87: Chlorine–deuterium exchange promoted by a palladium catalyst.
Scheme 88: Reaction of alkenyl chlorides with thiols in the presence of AIBN (azobisisobutyronitrile).
Scheme 89: Chloroalkene annulation.
Beilstein J. Org. Chem. 2025, 21, 2730–2738, doi:10.3762/bjoc.21.210
Graphical Abstract
Figure 1: Structures of prenylindole alkaloids derived from tryptophan.
Figure 2: Representative retrosynthetic considerations for 7-prenyl- and 7-allyltryptophan.
Scheme 1: C-7 Functionalization of 7-iodo-Nα-Boc-tryptophan methyl ester.
Scheme 2: C-7 Prenylation via C–H activation.
Figure 3: Negishi cross-coupling of allyl- and prenyl(iodo)indoles.
Scheme 3: Synthesis of prenyl- and allylindoles.
Scheme 4: Markovnikov hydrochlorination and hydrotrifluoroacetylation.
Scheme 5: Synthesis of asperdinones B–E 1–4.
Scheme 6: Control experiment.
Scheme 7: Control experiment of the Negishi cross-coupling reaction.
Scheme 8: Synthesis of terezine D and ent-asperdinone E.
Beilstein J. Org. Chem. 2025, 21, 2173–2201, doi:10.3762/bjoc.21.166
Graphical Abstract
Figure 1: Natural products and functional molecules possessing five-membered rings.
Scheme 1: Electrochemical intramolecular coupling of ureas to form indoles.
Scheme 2: Electrochemical dehydrogenative annulation of alkynes with anilines.
Scheme 3: Electrochemical annulations of o-arylalkynylanilines.
Scheme 4: Electrochemical cyclization of 2-ethynylanilines.
Scheme 5: Electrochemical selenocyclization of diselenides and 2-ethynylanilines.
Scheme 6: Electrochemical cascade approach towards 3-selenylindoles.
Scheme 7: Electrochemical C–H indolization.
Scheme 8: Electrochemical annulation of benzamides and terminal alkynes.
Scheme 9: Electrochemical synthesis of isoindolinone by 5-exo-dig aza-cyclization.
Scheme 10: Electrochemical reductive cascade annulation of o-alkynylbenzamide.
Scheme 11: Electrochemical intramolecular 1,2-amino oxygenation of alkyne.
Scheme 12: Electrochemical multicomponent reaction of nitrile, (thio)xanthene, terminal alkyne and water.
Scheme 13: Electrochemical aminotrifluoromethylation/cyclization of alkynes.
Scheme 14: Electrochemical cyclization of o-nitrophenylacetylene.
Scheme 15: Electrochemical annulation of alkynyl enaminones.
Scheme 16: Electrochemical annulation of alkyne and enamide.
Scheme 17: Electrochemical tandem Michael addition/azidation/cyclization.
Scheme 18: Electrochemical [3 + 2] cyclization of heteroarylamines.
Scheme 19: Electrochemical CuAAC to access 1,2,3-triazole.
Beilstein J. Org. Chem. 2025, 21, 915–925, doi:10.3762/bjoc.21.74
Graphical Abstract
Figure 1: Representative diazepine-fused heterocycles.
Scheme 1: Post-Ugi synthesis of benzodiazepines and heteroaryl-fused diazepines.
Scheme 2: Synthesis of pyrazole-tethered propargylamides 15 via U4CR. Conditions: Unless otherwise specified,...
Scheme 3: Scope of the silver(I) triflate-catalyzed synthesis of pyrazolo[1,5-a][1,4]diazepines. Conditions: ...
Scheme 4: Telescope procedure for the synthesis of 16a.
Scheme 5: Tentative mechanism for the silver-catalyzed heteroannulation.
Scheme 6: Reductive post-assembly modifications of the pyrazolo[1,5-a][1,4]diazepine core. aDetermined by 1H ...
Beilstein J. Org. Chem. 2025, 21, 630–638, doi:10.3762/bjoc.21.50
Graphical Abstract
Figure 1: Selected examples of α,α-disubstituted cyclic amino acids in drug design.
Figure 2: Electrochemical decarboxylative amination reactions.
Scheme 1: Preparation of malonic acid monoester 9a.
Figure 3: A) Cyclic voltammograms of 6a and 9a at 3 mM and 6 mM concentration, respectively, in 5:1 MeCN/H2O ...
Scheme 2: Electrolysis of acid 9d in deuterated solvents.
Figure 4: Plausible mechanism for formation of pyrrolidine 6a and hemiaminal 10a.
Scheme 3: Scope of the decarboxylative amidation. aStainless-steel cathode; bgraphite cathode; cyield determi...
Scheme 4: Synthetic modifications of 2-aminoproline derivatives 6.
Beilstein J. Org. Chem. 2024, 20, 2827–2833, doi:10.3762/bjoc.20.238
Graphical Abstract
Scheme 1: Synthesis of polyfunctionalized methane derivatives through successive nucleophilic additions to th...
Scheme 2: Cyclization of 4a quenched by D2O.
Scheme 3: Plausible mechanisms for the ring closure of 4.
Scheme 4: Hydration of the ethynyl group of 4a.
Beilstein J. Org. Chem. 2024, 20, 921–930, doi:10.3762/bjoc.20.82
Graphical Abstract
Figure 1: Advantages of acyl fluorides compared to acyl chlorides, previous work on BT-SRF reagents [29-33] and a su...
Scheme 1: Scope of the BT-SCF3-mediated deoxygenative fluorination of carboxylic acids 1. Reactions were perf...
Scheme 2: Scope of the one-pot BT-SCF3-mediated deoxygenative coupling of carboxylic acids and amines via acy...
Scheme 3: One-pot BT-SCF3-mediated deoxygenative coupling of amino acids. Isolated yields after column chroma...
Scheme 4: Plausible mechanism for the deoxyfluorination of carboxylic acids with BT-SCF3.
Scheme 5: Mechanistic experiments. (a) Conversion of thioester 3a into acyl fluoride 2a in the presence of DI...
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Beilstein J. Org. Chem. 2023, 19, 434–439, doi:10.3762/bjoc.19.33
Graphical Abstract
Scheme 1: Synthetic strategy towards 5 and 7.
Scheme 2: Synthesis of 9 and 11. (a) R = -CH3; (b) R = -CH(CH3)2; (c) R = -CH2CH(CH3)2; (d) R = -CH(CH3)CH2CH3...
Figure 1: Dixon plot for the hydrolysis of Gly-Phe-pNA substrate catalyzed by bovine cathepsin C in the prese...
Beilstein J. Org. Chem. 2022, 18, 1720–1740, doi:10.3762/bjoc.18.182
Graphical Abstract
Scheme 1: Automated in-line chromatography with the Advion puriFlash® system. The rightmost part of the schem...
Scheme 2: Purification via pH tuning and several Zaiput membranes. Redrawn from [51].
Scheme 3: Two-phase recirculating system for purifications of an immobilized enzyme-based reaction. Redrawn f...
Scheme 4: Countercurrent L–L purification using large Zaiput membranes in the presence of a phase transfer ca...
Scheme 5: General scheme of a telescoped flow process using L–L separators.
Scheme 6: Example of phase separation using a computer-vision approach. Redrawn from [68].
Scheme 7: Example of an inline purification using heterogeneous scavenging. Redrawn from [76].
Scheme 8: General scheme of a telescoped process using heterogenous cartridges.
Scheme 9: Comparison of two strategies for flow-based imatinib syntheses. Redrawn from [91] and [92].
Scheme 10: General purification scheme using the catch and release strategy.
Scheme 11: Exemplar catch and release purification of a stereoselective oxidation. Redrawn from [105].
Scheme 12: Catch and release-type purification using conventional SiO2. Redrawn from [107].
Scheme 13: Schematic representation of an industrial continuous crystallization. Redrawn from [109].
Scheme 14: General scheme of an academic inline crystallization approach.
Scheme 15: Simplified overview of purification options and selected criteria.
Beilstein J. Org. Chem. 2021, 17, 2924–2931, doi:10.3762/bjoc.17.201
Graphical Abstract
Figure 1: a) Structures of hoshinoamides A and B. b) Structure of hoshinoamide C.
Scheme 1: Synthesis of resin-bound tripeptide 3 by SPPS. DIPEA: N,N-diisopropylethylamine; HCTU: O-(6-chloro-...
Scheme 2: Synthesis of dipeptide 6. HATU: 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorop...
Scheme 3: Synthesis of hoshinoamide A.
Beilstein J. Org. Chem. 2021, 17, 1733–1751, doi:10.3762/bjoc.17.122
Graphical Abstract
Scheme 1: Mn-catalyzed late-stage fluorination of sclareolide (1) and complex steroid 3.
Figure 1: Proposed reaction mechanism of C–H fluorination by a manganese porphyrin catalyst.
Scheme 2: Late-stage radiofluorination of biologically active complex molecules.
Figure 2: Proposed mechanism of C–H radiofluorination.
Scheme 3: Late-stage C–H azidation of bioactive molecules. a1.5 mol % of Mn(TMP)Cl (5) was used. bMethyl acet...
Figure 3: Proposed reaction mechanism of manganese-catalyzed C–H azidation.
Scheme 4: Mn-catalyzed late-stage C–H azidation of bioactive molecules via electrophotocatalysis. a2.5 mol % ...
Figure 4: Proposed reaction mechanism of electrophotocatalytic azidation.
Scheme 5: Manganaelectro-catalyzed late-stage azidation of bioactive molecules.
Figure 5: Proposed reaction pathway of manganaelectro-catalyzed late-stage C–H azidation.
Scheme 6: Mn-catalyzed late-stage amination of bioactive molecules. a3 Å MS were used. Protonation with HBF4⋅...
Figure 6: Proposed mechanism of manganese-catalyzed C–H amination.
Scheme 7: Mn-catalyzed C–H methylation of heterocyclic scaffolds commonly found in small-molecule drugs. aDAS...
Scheme 8: Examples of late-stage C–H methylation of bioactive molecules. aDAST activation. bFor insoluble sub...
Scheme 9: A) Mn-catalyzed late-stage C–H alkynylation of peptides. B) Intramolecular late-stage alkynylative ...
Figure 7: Proposed reaction mechanism of Mn(I)-catalyzed C–H alkynylation.
Scheme 10: Late-stage Mn-catalyzed C–H allylation of peptides and bioactive motifs.
Scheme 11: Intramolecular C–H allylative cyclic peptide formation.
Scheme 12: Late-stage C–H glycosylation of tryptophan analogues.
Scheme 13: Late-stage C–H glycosylation of tryptophan-containing peptides.
Scheme 14: Late-stage C–H alkenylation of tryptophan-containing peptides.
Scheme 15: A) Late-stage C–H macrocyclization of tryptophan-containing peptides and B) traceless removal of py...
Beilstein J. Org. Chem. 2021, 17, 1641–1688, doi:10.3762/bjoc.17.116
Graphical Abstract
Figure 1: Structure of DNA and PNA.
Figure 2: PNA binding modes: (A) PNA–dsDNA 1:1 triplex; (B) PNA–DNA–PNA strand-invasion triplex; (C) the Hoog...
Figure 3: Structure of P-form PNA–DNA–PNA triplex from reference [41]. (A) view in the major groove and (B) view ...
Figure 4: Structures of backbone-modified PNA.
Figure 5: Structures of PNA having α- and γ-substituted backbones.
Figure 6: Structures of modified nucleobases in PNA to improve Hoogsteen hydrogen bonding to guanine and aden...
Figure 7: Proposed hydrogen bonding schemes for modified PNA nucleobases designed to recognize pyrimidines or...
Figure 8: Modified nucleobases to modulate Watson–Crick base pairing and chemically reactive crosslinking PNA...
Figure 9: Examples of triplets formed by Janus-wedge PNA nucleobases (blue). R1 denotes DNA, RNA, or PNA back...
Figure 10: Examples of fluorescent PNA nucleobases. R1 denotes DNA, RNA, or PNA backbones.
Figure 11: Endosomal entrapment and escape pathways of PNA and PNA conjugates.
Figure 12: (A) representative cell-penetrating peptides (CPPs), (B) conjugation designs and linker chemistries....
Figure 13: Proposed delivery mode by pHLIP-PNA conjugates (A) the transmembrane section of pHLIP interacting w...
Figure 14: Structures of modified penetratin CPP conjugates with PNA linked through either disulfide (for stud...
Figure 15: Chemical structure of C9–PNA, a stable amphipathic (cyclic-peptide)–PNA conjugate.
Figure 16: Structures of PNA conjugates with a lipophilic triphenylphosphonium cation (TPP–PNA) through (A) th...
Figure 17: Structures of (A) chloesteryl–PNA, (B) cholate–PNA and (C) cholate–PNA(cholate)3.
Figure 18: Structures of PNA–GalNAc conjugates (A) (GalNAc)2K, (B) triantennary (GalNAc)3, and (C) trivalent (...
Figure 19: Vitamin B12–PNA conjugates with different linkages.
Figure 20: Structures of (A) neomycin B, (B) PNA–neamine conjugate, and (C) PNA–neosamine conjugate.
Figure 21: PNA clamp (red) binding to target DNA containing a mixture of sequences (A) PNA binds with higher a...
Figure 22: Rolling circle amplification using PNA openers (red) to invade a dsDNA target forming a P-loop. A p...
Figure 23: Molecular beacons containing generic fluorophores (Fl) and quenchers (Q) recognizing a complementar...
Figure 24: (A) Light-up fluorophores such as thiazole orange display fluorescence enhancement upon binding to ...
Figure 25: Templated fluorogenic detection of oligonucleotides using two PNAs. (A) Templated FRET depends on h...
Figure 26: Lateral flow devices use a streptavidin labeled strip on nitrocellulose paper to anchor a capture P...
Beilstein J. Org. Chem. 2021, 17, 461–484, doi:10.3762/bjoc.17.41
Graphical Abstract
Figure 1: Phosphonopeptides, phosphonodepsipeptides, peptides, and depsipeptides.
Figure 2: The diverse strategies for phosphonodepsipeptide synthesis.
Scheme 1: Synthesis of α-phosphonodepsidipeptides as inhibitors of leucine aminopeptidase.
Figure 3: Structure of 2-hydroxy-2-oxo-3-[(phenoxyacetyl)amino]-1,2-oxaphosphorinane-6-carboxylic acid (16).
Scheme 2: Synthesis of α-phosphonodepsidipeptide 17 as coupling partner for cyclen-containing phosphonodepsip...
Scheme 3: Synthesis of α-phosphonodepsidipeptides containing enantiopure hydroxy ester as VanX inhibitors.
Scheme 4: Synthesis of α-phosphonodepsidipeptides as VanX inhibitors.
Scheme 5: Synthesis of optically active α-phosphonodepsidipeptides as VanX inhibitors.
Scheme 6: The synthesis of phosphonodepsipeptides through a thionyl chloride-catalyzed esterification of N-Cb...
Scheme 7: Synthesis of α-phosphinodipeptidamide as a hapten.
Scheme 8: Synthesis of α-phosphonodepsioctapeptide 41.
Scheme 9: Synthesis of phosphonodepsipeptides via an in situ-generated phosphonochloridate.
Scheme 10: Synthesis of α-phosphonodepsitetrapeptides 58 as inhibitors of the aspartic peptidase pepsin.
Scheme 11: Synthesis of a β-phosphonodepsidipeptide library 64.
Scheme 12: Synthesis of another β-phosphonodepsidipeptide library.
Scheme 13: Synthesis of γ-phosphonodepsidipeptides.
Scheme 14: Synthesis of phosphonodepsipeptides 85 as folylpolyglutamate synthetase inhibitors.
Scheme 15: Synthesis of the γ-phosphonodepsitripeptide 95 as an inhibitor of γ-gutamyl transpeptidase.
Scheme 16: Synthesis of phosphonodepsipeptides as inhibitors and probes of γ-glutamyl transpeptidase.
Scheme 17: Synthesis of phosphonyl depsipeptides 108 via DCC-mediated condensation and oxidation.
Scheme 18: Synthesis of phosphonodepsipeptides 111 with BOP and PyBOP as coupling reagents.
Scheme 19: Synthesis of optically active phosphonodepsipeptides with BOP and PyBOP as coupling reagents.
Scheme 20: Synthesis of phosphonodepsipeptides with BroP and TPyCIU as coupling reagents.
Scheme 21: Synthesis of a phosphonodepsipeptide hapten with BOP as coupling reagent.
Scheme 22: Synthesis of phosphonodepsitripeptide with BOP as coupling reagent.
Scheme 23: Synthesis of norleucine-derived phosphonodepsipeptides 135 and 138.
Scheme 24: Synthesis of norleucine-derived phosphonodepsipeptides 141 and 144.
Scheme 25: Solid-phase synthesis of phosphonodepsipeptides.
Scheme 26: Synthesis of phosphonodepsidipeptides via the Mitsunobu reaction.
Scheme 27: Synthesis of γ-phosphonodepsipeptide via the Mitsunobu reaction.
Scheme 28: Synthesis of phosphonodepsipeptides via a multicomponent condensation reaction.
Scheme 29: Synthesis of phosphonodepsipeptides with a functionalized side-chain via a multicomponent condensat...
Scheme 30: High yielding synthesis of phosphonodepsipeptides via a multicomponent condensation.
Scheme 31: Synthesis of optically active phosphonodepsipeptides via a multicomponent condensation reaction.
Scheme 32: Synthesis of N-phosphoryl phosphonodepsipeptides.
Scheme 33: Synthesis of phosphonodepsipeptides via the alkylation of phosphonic monoesters.
Scheme 34: Synthesis of phosphonodepsipeptides as inhibitors of aspartic protease penicillopepsin.
Scheme 35: Synthesis of phosphonodepsipeptides as prodrugs.
Scheme 36: Synthesis of phosphonodepsithioxopeptides 198.
Scheme 37: Synthesis of phosphonodepsipeptides.
Scheme 38: Synthesis of phosphonodepsipeptides with C-1-hydroxyalkylphosphonic acid.
Scheme 39: Synthesis of phosphonodepsipeptides with C-1-hydroxyalkylphosphonate via the rhodium-catalyzed carb...
Scheme 40: Synthesis of phosphonodepsipeptides with a C-1-hydroxyalkylphosphonate motif via a copper-catalyzed...
Beilstein J. Org. Chem. 2021, 17, 293–318, doi:10.3762/bjoc.17.28
Graphical Abstract
Figure 1: Selected examples of 19F-labelled amino acid analogues used as probes in chemical biology.
Figure 2: (a) Sequences of the antimicrobial peptide MSI-78 and pFtBSer-containing analogs and cartoon repres...
Figure 3: (a) Chemical structures of a selection of trifluoromethyl tags. (b) Comparative analysis showing th...
Figure 4: (a) First bromodomain of Brd4 with all three tryptophan residues displayed in blue and labelled by ...
Figure 5: (a) Enzymatic hydroxylation of GBBNF in the presence of hBBOX (b) 19F NMR spectra showing the conve...
Figure 6: (a) In-cell enzymatic hydrolysis of the fluorinated anandamide analogue ARN1203 catalyzed by hFAAH....
Figure 7: (a) X-ray crystal structure of CAM highlighting the location the phenylalanine residues replaced by...
Figure 8: 19F PREs of 4-F, 5-F, 6-F, 7-FTrp49 containing MTSL-modified S52CCV-N. The 19F NMR resonances of ox...
Figure 9: 19F NMR as a direct probe of Ud NS1A ED homodimerization. Schematic representation showing the loca...
Figure 10: (a) Representative spectrum of a 182 μM sample of Aβ1-40-tfM35 at varying times indicating the majo...
Figure 11: Illustration of the conformational switch induced by SDS in 4-tfmF-labelled α-Syn. Also shown are t...
Figure 12: (a) Structural models of the Myc‐Max (left), Myc‐Max‐DNA (middle) and Myc‐Max‐BRCA1 complexes (righ...
Figure 13: (a) Side (left) and bottom (right) views of the pentameric apo ELIC X-ray structure (PDB ID: 3RQU) ...
Figure 14: (a) General structure of a selection of recently developed 19F-labelled nucleotides for their use a...
Figure 15: Monitoring biotransformation of the fluorinated pesticide cyhalothrin by the fungus C. elegans. The...
Figure 16: Following the biodegradation of emerging fluorinated pollutants by 19F NMR. The spectra are from cu...
Figure 17: Discovery of new fluorinated natural products by 19F NMR. The spectrum is of the culture supernatan...
Figure 18: Application of 19F NMR to investigate the biosynthesis of nucleocidin. The spectra are from culture...
Figure 19: Detection of new fluorofengycins (indicated by arrows) in culture supernatants of Bacillus sp. CS93...
Figure 20: Measurement of β-galactosidase activity in MCF7 cancer cells expressing lacZ using 19F NMR. The deg...
Figure 21: Detection of ions using 19F NMR. (a) Structure of TF-BAPTA and its 19F iCEST spectra in the presenc...
Figure 22: (a) The ONOO−-mediated decarbonylation of 5-fluoroisatin and 6-fluoroisatin. The selectivity of (b)...
Beilstein J. Org. Chem. 2020, 16, 2073–2079, doi:10.3762/bjoc.16.174
Graphical Abstract
Figure 1: Pharmacologically active nonracemic phosphonates with heterocyclic moieties.
Figure 2: Starting nonracemic 4-nitro-2-oxophosphonates.
Scheme 1: Intermolecular N-methylation of reduction product 7.
Scheme 2: Synthesis of pyrrolidinyl phosphonic acids 11a–d.
Figure 3: ORTEP diagram of (2R,3R,4S)-10a.
Scheme 3: Synthesis of tetrahydropyranylphosphonates 13a–f via diastereoselective Henry/acetalyzation reactio...
Figure 4: ORTEP diagram of (2S,3R,4S,5S,6R)-13b.
Scheme 4: Synthesis of (3,4-dihydro-2H-pyran-5-yl)phosphonate 14.
Beilstein J. Org. Chem. 2020, 16, 2007–2016, doi:10.3762/bjoc.16.167
Graphical Abstract
Figure 1: Schematic representation of binding models between organic cations (simple ammonium, guanidinium, S...
Figure 2: From Schmuck cations to cell-penetrating dipeptides, with schematic representation of the binding m...
Figure 3: Peptide tweezers and cyclic peptides with Schmuck cations for gene transfection.
Figure 4: Evolution from CPPs to CPDs and COCs.
Figure 5: Structure of a) the trifunctional transporter 23 and c) the HaloTag reporter 26. b) Schematic mecha...
Figure 6: CAPA assay for the complex 25, composed of three transporters 23 bound to one streptavidin 24 (with...
Figure 7: Examples from the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 8: Evaluation of the automated HC imaging of stable HGM cells with HaloTag–GFP on mitochondria, labele...
Figure 9: a) Automated HC imaging of the cellular uptake of 25, covering the concentration dependence for the...
Figure 10: Examples of automated HC imaging of transiently transfected HeLa cells with HaloTag–GFP on Golgi, l...
Figure 11: Evaluation of the automated HC imaging of the transiently transfected HeLa cells with HaloTag–GFP o...
Beilstein J. Org. Chem. 2020, 16, 1588–1595, doi:10.3762/bjoc.16.131
Graphical Abstract
Scheme 1: a) Building blocks included in this study. b) Antiparallel and parallel constitutional isomers of t...
Figure 1: HPLC–MS chromatograms of a reference library for all possible tripeptide dimers ([M + H]+ ions).
Figure 2: a) HPLC–MS chromatograms of the dimers (CFC)2 and templates YY and FF. b) Amplification of the peak...
Scheme 2: a) Synthesis of the parallel and antiparallel isomers p(CFC)2 and a(CFC)2. b) Templates FF. YY and ...
Figure 3: ITC of YY (30 mM) to a(CFC)2 (1.5 mM) in phosphate buffer (pH 7.4, 100 mM).
Figure 4: Continuously varied NMR measurements of a) p(CFC)2 to YY b) p(CFC)2 to FF c) a(CFC)2 to YY d) a(CFC)...
Figure 5: Job plots derived from the continuously varied NMR measurements of a) p(CFC)2 to YY b) p(CFC)2 to FF...
Beilstein J. Org. Chem. 2020, 16, 1022–1050, doi:10.3762/bjoc.16.91
Graphical Abstract
Figure 1: Categories I–V of fluorinated phenylalanines.
Scheme 1: Synthesis of fluorinated phenylalanines via Jackson’s method.
Scheme 2: Synthesis of all-cis-tetrafluorocyclohexylphenylalanines.
Scheme 3: Synthesis of ʟ-4-[sulfono(difluoromethyl)]phenylalanine (nPt: neopentyl, TCE: trichloroethyl).
Scheme 4: Synthesis of ʟ-4-[sulfono(difluoromethyl)]phenylalanine derivatives 17.
Scheme 5: Synthesis of fluorinated Phe analogues from Cbz-protected aminomalonates.
Scheme 6: Synthesis of tetrafluorophenylalanine analogues via the 3-methyl-4-imidazolidinone auxiliary 25.
Scheme 7: Synthesis of tetrafluoro-Phe derivatives via chiral auxiliary 31.
Scheme 8: Synthesis of 2,5-difluoro-Phe and 2,4,5-trifluoro-Phe via Schöllkopf reagent 34.
Scheme 9: Synthesis of 2-fluoro- and 2,6-difluoro Fmoc-Phe derivatives starting from chiral auxiliary 39.
Scheme 10: Synthesis of 2-[18F]FPhe via chiral auxiliary 43.
Scheme 11: Synthesis of FPhe 49a via photooxidative cyanation.
Scheme 12: Synthesis of FPhe derivatives via Erlenmeyer azalactone synthesis.
Scheme 13: Synthesis of (R)- and (S)-2,5-difluoro Phe via the azalactone method.
Scheme 14: Synthesis of 3-bromo-4-fluoro-(S)-Phe (65).
Scheme 15: Synthesis of [18F]FPhe via radiofluorination of phenylalanine with [18F]F2 or [18F]AcOF.
Scheme 16: Synthesis of 4-borono-2-[18F]FPhe.
Scheme 17: Synthesis of protected 4-[18F]FPhe via arylstannane derivatives.
Scheme 18: Synthesis of FPhe derivatives via intermediate imine formation.
Scheme 19: Synthesis of FPhe derivatives via Knoevenagel condensation.
Scheme 20: Synthesis of FPhe derivatives 88a,b from aspartic acid derivatives.
Scheme 21: Synthesis of 2-(2-fluoroethyl)phenylalanine derivatives 93 and 95.
Scheme 22: Synthesis of FPhe derivatives via Zn2+ complexes.
Scheme 23: Synthesis of FPhe derivatives via Ni2+ complexes.
Scheme 24: Synthesis of 3,4,5-trifluorophenylalanine hydrochloride (109).
Scheme 25: Synthesis of FPhe derivatives via phenylalanine aminomutase (PAM).
Scheme 26: Synthesis of (R)-2,5-difluorophenylalanine 115.
Scheme 27: Synthesis of β-fluorophenylalanine via 2-amino-1,3-diol derivatives.
Scheme 28: Synthesis of β-fluorophenylalanine derivatives via the oxazolidinone chiral auxiliary 122.
Scheme 29: Synthesis of β-fluorophenylalanine from pyruvate hemiketal 130.
Scheme 30: Synthesis of β-fluorophenylalanine (136) via fluorination of β-hydroxyphenylalanine (137).
Scheme 31: Synthesis of β-fluorophenylalanine from aziridine derivatives.
Scheme 32: Synthesis of β-fluorophenylalanine 136 via direct fluorination of pyruvate esters.
Scheme 33: Synthesis of β-fluorophenylalanine via fluorination of ethyl 3-phenylpyruvate enol using DAST.
Scheme 34: Synthesis of β-fluorophenylalanine derivatives using photosensitizer TCB.
Scheme 35: Synthesis of β-fluorophenylalanine derivatives using Selectflour and dibenzosuberenone.
Scheme 36: Synthesis of protected β-fluorophenylalanine via aziridinium intermediate 150.
Scheme 37: Synthesis of β-fluorophenylalanine derivatives via fluorination of α-hydroxy-β-aminophenylalanine d...
Scheme 38: Synthesis of β-fluorophenylalanine derivatives from α- or β-hydroxy esters 152a and 155.
Scheme 39: Synthesis of a series of β-fluoro-Phe derivatives via Pd-catalyzed direct fluorination of β-methyle...
Scheme 40: Synthesis of series of β-fluorinated Phe derivatives using quinoline-based ligand 162 in the Pd-cat...
Scheme 41: Synthesis of β,β-difluorophenylalanine derivatives from 2,2-difluoroacetaldehyde derivatives 164a,b....
Scheme 42: Synthesis of β,β-difluorophenylalanine derivatives via an imine chiral auxiliary.
Scheme 43: Synthesis of α-fluorophenylalanine derivatives via direct fluorination of protected Phe 174.
Figure 2: Structures of PET radiotracers of 18FPhe derivatives.
Figure 3: Structures of melfufen (179) and melphalan (180) anticancer drugs.
Figure 4: Structure of gastrazole (JB95008, 181), a CCK2 receptor antagonist.
Figure 5: Dual CCK1/CCK2 antagonist 182.
Figure 6: Structure of sitagliptin (183), an antidiabetic drug.
Figure 7: Structure of retaglpitin (184) and antidiabetic drug.
Figure 8: Structure of evogliptin (185), an antidiabetic drug.
Figure 9: Structure of LY2497282 (186) a DPP-4 inhibitor for the treatment of type II diabetes.
Figure 10: Structure of ulimorelin (187).
Figure 11: Structure of GLP1R (188).
Figure 12: Structures of Nav1.7 blockers 189 and 190.
Beilstein J. Org. Chem. 2020, 16, 956–965, doi:10.3762/bjoc.16.84
Graphical Abstract
Figure 1: General biosynthesis of fabclavine Ia (1) in X. budapestensis (A) and representation of a shortened...
Figure 2: Comparison of the fcl BGCs in Xenorhabdus and Photorhabdus strains responsible for the fabclavine b...
Beilstein J. Org. Chem. 2020, 16, 888–894, doi:10.3762/bjoc.16.80
Graphical Abstract
Scheme 1: Description of the starting materials 1a–f and 2a–f.
Scheme 2: Peptide coupling reactions, including the previous Fmoc cleavage.
Scheme 3: Cleavage of the fully protected peptides 6 and 7.
Beilstein J. Org. Chem. 2020, 16, 756–762, doi:10.3762/bjoc.16.69
Graphical Abstract
Figure 1: Chemical structure of PyFluor, PBSF and SulfoxFluor.
Scheme 1: Synthesis of 5.
Figure 2: Chemical structure bases.
Scheme 2: Synthesis of 11.
Scheme 3: Synthesis of 13 and 14.
Figure 3: Molecular structure of compound (1R,2S)-14c (ORTEP image).
Scheme 4: Synthesis of 15. aConditions are given in the Experimental section.
Beilstein J. Org. Chem. 2019, 15, 2922–2929, doi:10.3762/bjoc.15.286
Graphical Abstract
Figure 1: Chemical structures of naturally occurring argyrins with potent antipseudomonal activity.
Figure 2: The biosynthetic pathway for argyrin production in Cystobacter sp. SBCb004 (Arg1, radical SAM-depen...
Figure 3: Designed mutasynthons 9–14 for argyrin biosynthesis. Peptides are based on three amino acids and ad...
Scheme 1: Synthesis of tripeptide thioesters. Reagents and conditions: (a) SOCl2, EtOH, 78 °C; (b) IBCF, NMM,...
Scheme 2: Improved synthesis of the tripeptide thioester 14. Reagents and conditions: (a) SOCl2, EtOH, 78 °C;...
Figure 4: Analysis of mutasynthon 14 obtained via the convergent synthetic route by HPLC on a HILIC stationar...